Explorer›Medicine›Open Science
Research PaperResearchia:202602.16026

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Chloe Orkin

Abstract

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial --- Source: OpenAlex - The Lancet (Citations: 2) PDF: N/A Original Link: https://doi.org/https://doi.org/10.1016/s0140-6736(25)01945-2

Submitted: February 16, 2026Subjects: Open Science; Medicine

Description / Details

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Source: OpenAlex - The Lancet (Citations: 2) PDF: N/A Original Link: https://doi.org/https://doi.org/10.1016/s0140-6736(25)01945-2

Please sign in to join the discussion.

No comments yet. Be the first to share your thoughts!

Access Paper
Submission Info
Date:
Feb 16, 2026
Topic:
Medicine
Area:
Open Science
Comments:
0
Bookmark
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial | Researchia